EASL 2017: Curing Hepatitis C Reduces Cardiovascular Risk

Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, according to a large French study presented this week at the International Liver Congress in Amsterdam.

Read more:

Hepatitis C Associated with Increased Risk of Head and Neck Cancers

Infection with hepatitis C virus (HCV) is associated with an increased risk of head and neck cancers, U.S. investigators reported recently in the Journal of the National Cancer Institute. The risk of certain cancers was especially high for patients who were also infected with human papillomavirus (HPV). Overall, hepatitis C was associated with an almost 3-fold increase in the risk of head and neck cancers.

Read more:

Coverage of the 2016 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.

Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.

Full coverage listing by topic

The Liver Meeting website

11/20/16

Direct-Acting Antivirals Reduce Cryoglobulinemia in People with Hepatitis C

Treatment with direct-acting antivirals not only cures people of hepatitis C, but can also rapidly reduce the severity of one of the most troublesome extra-hepatic manifestations of the disease, a study published in the February edition of Hepatology shows.

Read more: